Year: 2024

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Written by Customer Service on October 22, 2024. Posted in Public Companies.

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024 PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2024) in Seoul, South Korea. Details of the presentation are as follows: Date: Wednesday, October 23, 2024Session time: 08:30-10:10...

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Written by Customer Service on October 22, 2024. Posted in Public Companies.

Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammationWESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs...

Sify reports Consolidated Financial Results for Q2 FY 2024-25

Written by Customer Service on October 22, 2024. Posted in Earnings Releases And Operating Results.

Revenues of INR 10275 Million. EBITDA of INR 1963 Million. Profit for the period INR 49 Million. CHENNAI, India, Oct. 22, 2024 (GLOBE NEWSWIRE) — EARNINGS CALL DETAILS October, 22, 2024 | 8:30 AM ET Participant Dial in: To join: +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International) | Access Code: 407924 On the call: Mr. Raju Vegesna, Chairman of the Board, Mr. M P Vijay Kumar, Executive Director & Group CFO and Mr. Kamal Nath, Chief Executive Officer Live webcast: https://www.webcaster4.com/Webcast/Page/2184/51465 Archives: +1-877-481-4010 (Toll Free in the U.S. or Canada) or +1-919-882-2331 (International). On prompt, please enter passcode 51465. Replay is available until October 29, 2024. ___________________________ HIGHLIGHTSRevenue was INR 10275 Million, an increase of 17% over the same...

Verizon delivers strong third quarter results with customer growth in mobility, extending industry leadership

Written by Customer Service on October 22, 2024. Posted in Earnings Releases And Operating Results.

Achieves fixed wireless subscriber target 15 months ahead of schedule and double-digit growth in total broadband connections Company remains on track to meet full-year 2024 financial guidance 3Q 2024 Highlights Wireless: More than doubled wireless postpaid phone net additions year over yearTotal wireless service revenue1 of $19.8 billion, a 2.7 percent increase year over year. Retail postpaid phone net additions of 239,000, and retail postpaid net additions of 349,000. Retail postpaid phone churn of 0.89 percent, and retail postpaid churn of 1.16 percent.Broadband: Achieved fixed wireless subscriber target 15 months ahead of scheduleTotal broadband net additions of 389,000. This was the ninth consecutive quarter with more than 375,000 broadband net additions. Total fixed wireless net additions of 363,000. At the end of third-quarter...

Denny’s Corporation Reports Results for Third Quarter 2024 and Hosts Investor Day Today

Written by Customer Service on October 22, 2024. Posted in Earnings Releases And Operating Results.

SPARTANBURG, S.C., Oct. 22, 2024 (GLOBE NEWSWIRE) — Denny’s Corporation (the “Company”) (NASDAQ: DENN), owner and operator of Denny’s Inc. (“Denny’s”) and Keke’s Inc. (“Keke’s”) today reported results for its third quarter ended September 25, 2024 and provided a business update on the Company’s operations. Kelli Valade, Chief Executive Officer, stated, “Our third quarter sales results directly reflect ongoing brand investments and dedicated focus on value that resulted in outpacing the category. Denny’s domestic system-wide same-restaurant sales** outperformed the BBI Family Dining index for the third consecutive quarter driven by the relaunch of our fan favorite $2-$4-$6-$8 value menu and the continued expansion of off-premises with our third virtual brand, Banda Burrito....

Capital City Bank Group, Inc. Reports Third Quarter 2024 Results

Written by Customer Service on October 22, 2024. Posted in Earnings Releases And Operating Results.

TALLAHASSEE, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) today reported net income attributable to common shareowners of $13.1 million, or $0.78 per diluted share, for the third quarter of 2024 compared to $14.2 million, or $0.83 per diluted share, for the second quarter of 2024, and $12.7 million, or $0.74 per diluted share, for the third quarter of 2023. QUARTER HIGHLIGHTS (3rd Quarter 2024 versus 2nd Quarter 2024) Income StatementTax-equivalent net interest income totaled $40.3 million compared to $39.3 million for the prior quarterNet interest margin increased 10 basis points to 4.12% (earning asset yield up 7 basis points and total deposit cost down 3 basis points to 92 basis points)Stable credit quality metrics and credit loss provision – net loan charge-offs were 19...

Interpublic Announces Third Quarter and First Nine Months 2024 Results

Written by Customer Service on October 22, 2024. Posted in Earnings Releases And Operating Results.

New York, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) —Total revenue including billable expenses was $2.63 billion Revenue before billable expenses (“net revenue”) was $2.24 billion, with organic revenue unchanged from the third quarter of 2023 Non-cash goodwill impairment expense of $232.1 million, related to digital specialist agencies and the sale process for R/GA and Huge Reported net income was $20.1 million Adjusted EBITA was $385.8 million Margin of adjusted EBITA was 17.2% on revenue before billable expenses Diluted earnings per share including goodwill charge was $0.05 as reported and $0.70 as adjustedPhilippe Krakowsky, CEO of Interpublic: “Net revenue in the third quarter was unchanged organically from the same period a year ago, which brings organic growth over the first nine months of this year to 1.0%. During...

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Written by Customer Service on October 22, 2024. Posted in Public Companies.

– CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD – – Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) – – Versatility of SCS Microinjector® Featured in Multiple Presentations – ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmology (AAO) and preceding events that highlighted encouraging safety and efficacy data from clinical trials of therapies utilizing Clearside’s SCS...

Lithium Ionic Initiates Engineering and Construction Management Services Contracts, Awarded to Hatch and Reta for Bandeira Project Development

Written by Customer Service on October 22, 2024. Posted in Public Companies.

TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) is pleased to announce the initiation of Engineering, Procurement, and Construction Management (“EPCM”) services for its flagship Bandeira Lithium Project (“Bandeira” or the “Project”) located in northeastern Minas Gerais State, Brazil. This milestone marks the transition to the construction and development phase of the Project and is a key step towards production. Advancing engineering and construction management services will progress the Project along the targeted timeline in anticipation of the upcoming approval of site permits. Key Highlights:Hatch Ltd. has been awarded engineering and design services. Hatch is an internationally recognized engineering firm with extensive global experience...

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Written by Customer Service on October 22, 2024. Posted in Public Companies.

Determined the high dose of OCU410ST to be the maximum tolerated dose No serious adverse events have been reported Approved proceeding to Phase 2 using high and medium doses of OCU410STMALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical trial. OCU410ST (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for Stargardt disease. “The DSMB has recommended moving forward with Phase 2 enrollment, as safety data indicates that OCU410ST appears...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals